Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival.

Fennec Pharmaceuticals, Inc. Capital Structure

13.6million shares outstanding.

1.3million shares upon exercise at USD $1.50, warrants expire on November 22, 2018